Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06717243 · ClinicalTrials.gov registry record
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
A clinical trial of Small-cell Lung Cancer and Immunotherapy, sponsored by Oncology Center of Biochemical Education And Research.
- Recruiting
- Registry status
- 111
- Enrollment target
- 2
- Study locations
NCT06717243 is a study of Small-cell Lung Cancer and Immunotherapy that is actively recruiting participants, run by Oncology Center of Biochemical Education And Research. The registered enrollment target is 111 participants, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06717243, a study of Small-cell Lung Cancer and Immunotherapy, is actively recruiting participants, sponsored by Oncology Center of Biochemical Education And Research.
- RECRUITING
- Registry status
- 111 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine carcinoma (LCNEC). Both ES-SCLC and LCNEC are aggressive forms of lung cancer with limited treatment options and poor prognosis. While initial responses to chemo-immunotherapy are often promising, most patients develop resistance within a few months, resulting in disease progression and limited survival. This study seeks to explore the molecular and cellular changes that drive resistance, providing insights that could guide more personalized and effective treatment strategies in the future. The study focuses on identifying genomic and methylation signatures, as well as analyzing circulating tumor cells (CTCs) and tumor DNA (ctDNA), to better understand the mechanisms of resistance. By collecting and analyzing these biomarkers over time, researchers aim to identify patterns that distinguish patients who benefit long-term from therapy from those who experience early resistance. These findings may pave the way for new diagnostic tools and therapies to predict and overcome resistance to chemo-immunotherapy. The main questions this study seeks to answer are: Are there specific genomic or methylation patterns that predict resistance to chemo-immunotherapy in ES-SCLC and LCNEC? How are circulating tumor cells (CTCs) and tumor DNA (ctDNA) associated with disease progression, treatment response, and survival? What molecular differences exist between patients who respond long-term and those who develop resistance early in their treatment? Participants will: Provide blood and tumor tissue samples before treatment to establish baseline molecular profiles. Undergo follow-up visits every 9 weeks during treatment, where additional blood samples and imaging tests will be collected to monitor disease progression and treatment
Conditions Studied
Interventions
- DRUG Carboplatin/Cisplatin -Etoposide - Atezolizumab
Study Locations (2)
New York
- Icahn School of Medicine at Mount Sinai - New York
Other
- 3rd Department of Medicine, National and Kapodistrian University of Athens, Sotiria Hospital - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2025-02-20 |
| Est. Completion | 2028-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06717243
The ClinicalTrials.gov registry entry for NCT06717243 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (52% lower). The listed sponsor is Oncology Center of Biochemical Education And Research, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Carboplatin/Cisplatin -Etoposide - Atezolizumab is the first listed.
NCT06717243 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Other.
Frequently Asked Questions
What is clinical trial NCT06717243 about?
NCT06717243 is a clinical study titled "Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)". The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine carcinoma (LCNEC). Both ES-SCLC and LCNEC ar...
What is the current status of trial NCT06717243?
This trial is currently recruiting. The enrollment target is 111 participants. The study started on 2025-02-20. Estimated completion is 2028-12-01.
What conditions does trial NCT06717243 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Immunotherapy, Biomarkers, Treatment Failure, Biomarkers / Blood.
What interventions are being tested in trial NCT06717243?
The interventions under investigation include: Carboplatin/Cisplatin -Etoposide - Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT06717243?
This trial is sponsored by Oncology Center of Biochemical Education And Research, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06717243 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
RECRUITING
-
A Study of Hospital-at-Home for People Receiving Tarlatamab
RECRUITING · NA
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.